EYPT vs. TRNS

Last updated Apr 2, 2026

Compare and contrast key facts about Eyepoint Pharmaceuticals Inc (EYPT) and Transcat, Inc. (TRNS).

Performance

EYPT vs. TRNS - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Eyepoint Pharmaceuticals Inc (EYPT) and Transcat, Inc. (TRNS). The values are adjusted to include any dividend payments, if applicable.

EYPT vs. TRNS - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
EYPT Eyepoint Pharmaceuticals Inc	-28.74%	145.23%	-67.76%	560.29%	-71.41%	86.02%	-57.55%	-17.99%	75.00%	-36.84%
TRNS Transcat, Inc.	31.34%	-46.35%	-3.28%	54.27%	-23.33%	166.52%	8.85%	67.51%	33.47%	31.94%

Fundamentals

Market Cap EYPT : $1.08B TRNS : $695.10M
EPS EYPT : -$3.12 TRNS : $0.97
PS Ratio EYPT : 30.87 TRNS : 2.17
PB Ratio EYPT : 3.53 TRNS : 2.34
Total Revenue (TTM) EYPT : $31.37M TRNS : $320.40M
Gross Profit (TTM) EYPT : $29.31M TRNS : $103.84M
EBITDA (TTM) EYPT : -$239.53M TRNS : $34.58M

Returns By Period

In the year-to-date period, EYPT achieves a -28.74% return, which is significantly lower than TRNS's 31.34% return. Over the past 10 years, EYPT has underperformed TRNS with an annualized return of -7.34%, while TRNS has yielded a comparatively higher 22.12% annualized return.

EYPT

• 1D: 1.01%
• 1M: -29.01%
• YTD: -28.74%
• 6M: 0.81%
• 1Y: 157.82%
• 3Y*: 64.22%
• 5Y*: 3.79%
• 10Y*: -7.34%

TRNS

• 1D: 1.44%
• 1M: -7.70%
• YTD: 31.34%
• 6M: 3.75%
• 1Y: 0.47%
• 3Y*: -5.89%
• 5Y*: 8.78%
• 10Y*: 22.12%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

EYPT vs. TRNS — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

EYPT

EYPT Risk / Return Rank: 88
EYPT Sharpe Ratio Rank: 91
EYPT Sortino Ratio Rank: 88
EYPT Omega Ratio Rank: 84
EYPT Calmar Ratio Rank: 88
EYPT Martin Ratio Rank: 88

TRNS

TRNS Risk / Return Rank: 39
TRNS Sharpe Ratio Rank: 40
TRNS Sortino Ratio Rank: 38
TRNS Omega Ratio Rank: 37
TRNS Calmar Ratio Rank: 40
TRNS Martin Ratio Rank: 40

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

EYPT vs. TRNS - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Eyepoint Pharmaceuticals Inc (EYPT) and Transcat, Inc. (TRNS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	EYPT	TRNS	Difference
Sharpe ratio Return per unit of total volatility	2.11	0.01	+2.10
Sortino ratio Return per unit of downside risk	2.75	0.38	+2.37
Omega ratio Gain probability vs. loss probability	1.33	1.04	+0.28
Calmar ratio Return relative to maximum drawdown	3.78	0.00	+3.77
Martin ratio Return relative to average drawdown	9.96	0.00	+9.96
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

EYPT vs. TRNS - Sharpe Ratio Comparison

The current EYPT Sharpe Ratio is 2.11, which is higher than the TRNS Sharpe Ratio of 0.01. The chart below compares the historical Sharpe Ratios of EYPT and TRNS, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	EYPT	TRNS	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.11	0.01	+2.10
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.03	0.20	-0.17
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	-0.07	0.53	-0.60
Sharpe Ratio (All Time) Calculated using the full available price history	-0.09	0.16	-0.25

Correlation

The correlation between EYPT and TRNS is 0.10, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

EYPT vs. TRNS - Dividend Comparison

Neither EYPT nor TRNS has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

EYPT vs. TRNS - Drawdown Comparison

The maximum EYPT drawdown since its inception was -97.73%, roughly equal to the maximum TRNS drawdown of -93.42%. Use the drawdown chart below to compare losses from any high point for EYPT and TRNS.

Drawdown Indicators

	EYPT	TRNS	Difference
Max Drawdown Largest peak-to-trough decline	-97.73%	-93.42%	-4.31%
Max Drawdown (1Y) Largest decline over 1 year	-37.14%	-44.83%	+7.69%
Max Drawdown (5Y) Largest decline over 5 years	-87.61%	-63.86%	-23.75%
Max Drawdown (10Y) Largest decline over 10 years	-94.45%	-63.86%	-30.59%
Current Drawdown Current decline from peak	-87.03%	-48.28%	-38.75%
Average Drawdown Average peak-to-trough decline	-76.33%	-35.33%	-41.00%
Ulcer Index Depth and duration of drawdowns from previous peaks	14.08%	23.78%	-9.70%

Volatility

EYPT vs. TRNS - Volatility Comparison

Eyepoint Pharmaceuticals Inc (EYPT) has a higher volatility of 20.37% compared to Transcat, Inc. (TRNS) at 12.12%. This indicates that EYPT's price experiences larger fluctuations and is considered to be riskier than TRNS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	EYPT	TRNS	Difference
Volatility (1M) Calculated over the trailing 1-month period	20.37%	12.12%	+8.25%
Volatility (6M) Calculated over the trailing 6-month period	51.23%	34.84%	+16.39%
Volatility (1Y) Calculated over the trailing 1-year period	75.69%	48.01%	+27.68%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	118.59%	43.20%	+75.39%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	100.71%	42.17%	+58.54%

Financials